Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data.
Saved in:
| Title: | Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. |
|---|---|
| Authors: | Fitzgerald L; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City.; George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT., Ghosh S; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Khan W; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Bokun A; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Lax A; Analysis Group, Inc., Boston, MA., Mu F; Analysis Group, Inc., Boston, MA., Cook EE; Analysis Group, Inc., Boston, MA., Chen J; Analysis Group, Inc., Boston, MA., Chen G; Analysis Group, Inc., Boston, MA., Wu E; Analysis Group, Inc., Boston, MA., Lin Y; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans., Shi L; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans., Qureshi ZP; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA., Graf SA; Division of Hematology/Oncology, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA. |
| Source: | Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2026 Feb; Vol. 32 (2), pp. 186-200. Date of Electronic Publication: 2025 Dec 03. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41334748 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Fitzgerald+L%22">Fitzgerald L</searchLink>; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City.; George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Ghosh+S%22">Ghosh S</searchLink>; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA.<br /><searchLink fieldCode="AU" term="%22Khan+W%22">Khan W</searchLink>; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA.<br /><searchLink fieldCode="AU" term="%22Bokun+A%22">Bokun A</searchLink>; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA.<br /><searchLink fieldCode="AU" term="%22Lax+A%22">Lax A</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Mu+F%22">Mu F</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cook+EE%22">Cook EE</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Chen+G%22">Chen G</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wu+E%22">Wu E</searchLink>; Analysis Group, Inc., Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lin+Y%22">Lin Y</searchLink>; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans.<br /><searchLink fieldCode="AU" term="%22Shi+L%22">Shi L</searchLink>; Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.; Southeast Louisiana Veterans Health Care System, New Orleans.<br /><searchLink fieldCode="AU" term="%22Qureshi+ZP%22">Qureshi ZP</searchLink>; Janssen Scientific Affairs, a Johnson & Johnson Company, Horsham, PA.<br /><searchLink fieldCode="AU" term="%22Graf+SA%22">Graf SA</searchLink>; Division of Hematology/Oncology, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101644425%22">Journal of managed care & specialty pharmacy</searchLink> [J Manag Care Spec Pharm] 2026 Feb; Vol. 32 (2), pp. 186-200. <i>Date of Electronic Publication: </i>2025 Dec 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academy+of+Managed+Care+Pharmacy%22">Academy of Managed Care Pharmacy </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101644425 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2376-1032 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223760540%22">23760540 </searchLink><i>NLM ISO Abbreviation: </i>J Manag Care Spec Pharm <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41334748 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.18553/jmcp.2025.25169 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 186 Titles: – TitleFull: Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fitzgerald L – PersonEntity: Name: NameFull: Ghosh S – PersonEntity: Name: NameFull: Khan W – PersonEntity: Name: NameFull: Bokun A – PersonEntity: Name: NameFull: Lax A – PersonEntity: Name: NameFull: Mu F – PersonEntity: Name: NameFull: Cook EE – PersonEntity: Name: NameFull: Chen J – PersonEntity: Name: NameFull: Chen G – PersonEntity: Name: NameFull: Wu E – PersonEntity: Name: NameFull: Lin Y – PersonEntity: Name: NameFull: Shi L – PersonEntity: Name: NameFull: Qureshi ZP – PersonEntity: Name: NameFull: Graf SA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2026 Feb Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2376-1032 Numbering: – Type: volume Value: 32 – Type: issue Value: 2 Titles: – TitleFull: Journal of managed care & specialty pharmacy Type: main |
| ResultId | 1 |